Manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), Cambrex, is expanding its High Point, North Carolina facility with the addition of a new $3.2 million, 11,000 sq ft analytical laboratory.
Expansion
“There is a growing demand in the industry to better understand and characterise APIs and process intermediates at the clinical stage,” commented Brian Swierenga, VP, operations and site director for Cambrex High Point. “This expansion reinforces Cambrex’s position as a leader in small molecule API clinical and commercial manufacturing while enabling the organisation to stay ahead of regulatory requirements.”
Equipment to be installed at the facility as part of the expansion will include HPLCs, mass spectrometers and support equipment. It is anticipated that validation and start-up of the expansion will begin in the last quarter of the year.
Additionally, through this site expansion, Cambrex will add twelve new analytical development scientists to the R&D team.